• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
PSTI

PSTI

Pluristem Therapeutics Inc.

NASDAQHealthcareBiotechnologyIL

USD1.00

-0.03 (-2.91%)

Company Profile

CEO

Yaky Yanay

IPO Date

2007-12-10

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

IL

Market Metrics

Open

$1.02

Prev. Close

$1.03

Day Low

$0.96

Day High

$1.04

Market Cap

$0.04B

Volume

0.17M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

41.2%

Avg Negative

10.5%

Avg Neutral

48.3%

News Feed

Pluristem Appoints Prof. Varda Shalev MD and Mr.

GlobeNewsWire·7/19/2021·↑ positive

Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout

GlobeNewsWire·7/8/2021·↑ positive

Cathie Wood's ARK Invest Sells 194,000 Shares of Pluristem Therapeutics

24/7 Wall Street·6/5/2021·↑ positive

Pluristem Stock is Trading Higher After €20M Non-Dilutive Funding from European Investment Bank

Benzinga·5/25/2021·↑ positive

PSTI Stock: From $4.52 To Over $4.90 Pre-Market Explanation

Pulse2·4/29/2021·↑ positive

Longeveron Seeks $25 Million IPO For Anti-Aging Efforts

Seeking Alpha·2/5/2021·↑ positive

Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering

GlobeNewsWire·2/2/2021·↑ positive

ARKG: Potential Disruption For Healthcare And Pharma Industries

Seeking Alpha·1/19/2021·↓ negative

Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem's ARDS Associated With COVID-19 Program to Mexico

GlobeNewsWire·12/29/2020·↑ positive

Pluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study

GlobeNewsWire·12/9/2020·↑ positive